DD146594B3 - Verfahren zur herstellung von prostanderivaten - Google Patents

Verfahren zur herstellung von prostanderivaten Download PDF

Info

Publication number: DD146594B3
Authority: DD; German Democratic Republic
Prior art keywords: hydroxy; group; solution; stirred; substituted
Prior art date: 1978-10-19

Application number

DD79216259A

Other languages

German (de)

English (en)

Other versions

DD146594A5 (de

Inventor

Werner Skuballa

Bernd Raduechel

Helmut Vorbrueggen

Gerda Mannesmann

Wolfgang Losert

Jorge Casals

Original Assignee

Werner Skuballa

Bernd Raduechel

Helmut Vorbrueggen

Gerda Mannesmann

Wolfgang Losert

Jorge Casals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-19

Filing date

1979-10-16

Publication date

1989-09-06

1979-10-16 Application filed by Werner Skuballa, Bernd Raduechel, Helmut Vorbrueggen, Gerda Mannesmann, Wolfgang Losert, Jorge Casals filed Critical Werner Skuballa

1981-02-18 Publication of DD146594A5 publication Critical patent/DD146594A5/de

1989-09-06 Publication of DD146594B3 publication Critical patent/DD146594B3/de

Links

210000002307 prostate Anatomy 0.000 title description 2
238000004519 manufacturing process Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 56
-1 carboxy, hydroxy Chemical group 0.000 claims abstract description 43
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
239000001257 hydrogen Substances 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
125000002947 alkylene group Chemical group 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 5
230000008569 process Effects 0.000 claims description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 83
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 7
150000003180 prostaglandins Chemical class 0.000 abstract description 6
229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 4
125000002252 acyl group Chemical group 0.000 abstract description 3
230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
150000002431 hydrogen Chemical group 0.000 abstract description 2
125000000041 C6-C10 aryl group Chemical group 0.000 abstract 8
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
125000005843 halogen group Chemical group 0.000 abstract 5
125000006546 (C4-C10) cycloalkyl group Chemical group 0.000 abstract 4
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 abstract 4
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
229910052760 oxygen Inorganic materials 0.000 abstract 3
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
239000004215 Carbon black (E152) Substances 0.000 abstract 2
229930195733 hydrocarbon Natural products 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
125000006413 ring segment Chemical group 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
125000004450 alkenylene group Chemical group 0.000 abstract 1
125000004419 alkynylene group Chemical group 0.000 abstract 1
239000003705 antithrombocytic agent Substances 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
239000000243 solution Substances 0.000 description 77
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 64
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 40
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 39
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
239000012230 colorless oil Substances 0.000 description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
229910052943 magnesium sulfate Inorganic materials 0.000 description 32
235000019341 magnesium sulphate Nutrition 0.000 description 32
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 29
239000000203 mixture Substances 0.000 description 28
239000000741 silica gel Substances 0.000 description 28
229910002027 silica gel Inorganic materials 0.000 description 28
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
150000002576 ketones Chemical class 0.000 description 23
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
229910052786 argon Inorganic materials 0.000 description 20
238000004587 chromatography analysis Methods 0.000 description 20
239000003921 oil Substances 0.000 description 18
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 18
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
239000012267 brine Substances 0.000 description 16
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
230000007935 neutral effect Effects 0.000 description 14
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
229960000583 acetic acid Drugs 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
150000001299 aldehydes Chemical class 0.000 description 12
239000012043 crude product Substances 0.000 description 11
238000001704 evaporation Methods 0.000 description 11
230000008020 evaporation Effects 0.000 description 11
239000005457 ice water Substances 0.000 description 10
239000007858 starting material Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
238000000746 purification Methods 0.000 description 9
MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 8
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 7
150000002009 diols Chemical class 0.000 description 7
229910000027 potassium carbonate Inorganic materials 0.000 description 7
125000006239 protecting group Chemical group 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
229910000033 sodium borohydride Inorganic materials 0.000 description 7
239000012279 sodium borohydride Substances 0.000 description 7
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
239000000284 extract Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 5
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
238000007239 Wittig reaction Methods 0.000 description 5
230000036772 blood pressure Effects 0.000 description 5
229960001123 epoprostenol Drugs 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
238000003756 stirring Methods 0.000 description 5
SNRDFPUMRHPUCQ-UHFFFAOYSA-N CS(=O)C[Na] Chemical compound CS(=O)C[Na] SNRDFPUMRHPUCQ-UHFFFAOYSA-N 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
150000005690 diesters Chemical class 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
150000004679 hydroxides Chemical class 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
239000000047 product Substances 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
230000007017 scission Effects 0.000 description 4
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
ZOUYMLXOFDNVRK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-one Chemical compound C1CCC2CC(=O)CC21 ZOUYMLXOFDNVRK-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000006772 olefination reaction Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000007127 saponification reaction Methods 0.000 description 3
AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
239000012027 Collins reagent Substances 0.000 description 2
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910001854 alkali hydroxide Inorganic materials 0.000 description 2
150000001336 alkenes Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000003266 anti-allergic effect Effects 0.000 description 2
AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
239000000920 calcium hydroxide Substances 0.000 description 2
229910001861 calcium hydroxide Inorganic materials 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000004304 potassium nitrite Substances 0.000 description 2
235000010289 potassium nitrite Nutrition 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000000926 separation method Methods 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000008096 xylene Substances 0.000 description 2
AGCFEGOOERJXAB-SSJBICQBSA-N (1S,2R,4R,5S)-2-(2-ethoxy-2-oxoethyl)-1,2-dimethyl-4-(oxan-2-yloxy)-5-phenylmethoxycyclopentane-1-carboxylic acid Chemical compound C(C)OC(=O)C[C@@]1([C@@]([C@@H]([C@@H](C1)OC1OCCCC1)OCC1=CC=CC=C1)(C(=O)O)C)C AGCFEGOOERJXAB-SSJBICQBSA-N 0.000 description 1
FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 1
LLFMCCBDEXWDDP-HPUPVJTASA-N (3ar,4s,5r,6as)-5-(oxan-2-yloxy)-4-(phenylmethoxymethyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound O([C@@H]1C[C@H]2[C@@H]([C@H]1COCC=1C=CC=CC=1)CC(O2)=O)C1CCCCO1 LLFMCCBDEXWDDP-HPUPVJTASA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PQRJMMHOQSJORL-UHFFFAOYSA-N 1-dimethoxyphosphorylhept-5-yn-2-one Chemical compound COP(=O)(OC)CC(=O)CCC#CC PQRJMMHOQSJORL-UHFFFAOYSA-N 0.000 description 1
SLNMIHCDIBTGJX-UHFFFAOYSA-N 2-(3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene)pentanoic acid Chemical compound C12CC(CC2CCC1)=C(C(=O)O)CCC SLNMIHCDIBTGJX-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
SBXPCQUWKNIVJY-UHFFFAOYSA-N 3-ethyl-2-propyloct-2-enoic acid Chemical compound CCC(CCCCC)=C(C(=O)O)CCC SBXPCQUWKNIVJY-UHFFFAOYSA-N 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
101000878595 Arabidopsis thaliana Squalene synthase 1 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
AQOSUYULGIFJLY-UHFFFAOYSA-N C[S-]=O.[Na+] Chemical compound C[S-]=O.[Na+] AQOSUYULGIFJLY-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
239000003810 Jones reagent Substances 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
238000007295 Wittig olefination reaction Methods 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
OKSPIDPKTAWTNP-UIJPLUKJSA-N [(1'R,2'R,3'aR,6'aS)-1'-[(E)-3-oxooct-1-en-6-ynyl]spiro[1,3-dioxolane-2,5'-2,3,3a,4,6,6a-hexahydro-1H-pentalene]-2'-yl] benzoate Chemical compound C1OC2(C[C@H]3C[C@H]([C@@H]([C@H]3C2)\C=C\C(CCC#CC)=O)OC(C2=CC=CC=C2)=O)OC1 OKSPIDPKTAWTNP-UIJPLUKJSA-N 0.000 description 1
VQQXMLCOUNMWEM-UIJPLUKJSA-N [(1'r,2'r,3'ar,6'as)-1'-[(e)-3-oxooct-1-enyl]spiro[1,3-dioxolane-2,5'-2,3,3a,4,6,6a-hexahydro-1h-pentalene]-2'-yl] benzoate Chemical compound C([C@H]1C[C@H]([C@@H]([C@H]1C1)/C=C/C(=O)CCCCC)OC(=O)C=2C=CC=CC=2)C21OCCO2 VQQXMLCOUNMWEM-UIJPLUKJSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
QFFVPLLCYGOFPU-UHFFFAOYSA-N barium chromate Chemical compound [Ba+2].[O-][Cr]([O-])(=O)=O QFFVPLLCYGOFPU-UHFFFAOYSA-N 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003727 cerebral blood flow Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
238000005907 ketalization reaction Methods 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
235000021190 leftovers Nutrition 0.000 description 1
PKFSNWROLARCKD-WYTHCCDPSA-N methyl (1S,2R,4R,5S)-2-(2-ethoxy-2-oxoethyl)-2-methyl-4-(oxan-2-yloxy)-5-phenylmethoxycyclopentane-1-carboxylate Chemical compound C(C)OC(=O)C[C@@]1([C@@H]([C@@H]([C@@H](C1)OC1OCCCC1)OCC1=CC=CC=C1)C(=O)OC)C PKFSNWROLARCKD-WYTHCCDPSA-N 0.000 description 1
AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
238000007248 oxidative elimination reaction Methods 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
150000004714 phosphonium salts Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000036593 pulmonary vascular resistance Effects 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008327 renal blood flow Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
- C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
- C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
- C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Pyrane Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Networks Using Active Elements (AREA)
Mechanical Coupling Of Light Guides (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

DD79216259A 1978-10-19 1979-10-16 Verfahren zur herstellung von prostanderivaten DD146594B3 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19782845770 DE2845770A1 (de)	1978-10-19	1978-10-19	Neue prostacyclin-derivate und verfahren zu ihrer herstellung

Publications (2)

Publication Number	Publication Date
DD146594A5 DD146594A5 (de)	1981-02-18
DD146594B3 true DD146594B3 (de)	1989-09-06

Family

ID=6052699

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79216259A DD146594B3 (de)	1978-10-19	1979-10-16	Verfahren zur herstellung von prostanderivaten

Country Status (25)

Country	Link
US (1)	US4692464A (ru)
EP (1)	EP0011591B1 (ru)
JP (1)	JPS5557559A (ru)
AT (1)	ATE1283T1 (ru)
AU (1)	AU534090B2 (ru)
CA (1)	CA1181747A (ru)
CS (1)	CS219260B2 (ru)
DD (1)	DD146594B3 (ru)
DE (2)	DE2845770A1 (ru)
DK (1)	DK160246C (ru)
ES (1)	ES485199A1 (ru)
FI (1)	FI69056C (ru)
GR (1)	GR72247B (ru)
HU (1)	HU184926B (ru)
IE (1)	IE49085B1 (ru)
IL (1)	IL58475A (ru)
LU (1)	LU88288I2 (ru)
MX (1)	MX9203690A (ru)
NL (1)	NL930070I2 (ru)
NO (2)	NO151318C (ru)
NZ (1)	NZ191827A (ru)
PH (1)	PH20359A (ru)
SU (2)	SU1003754A3 (ru)
YU (1)	YU41668B (ru)
ZA (1)	ZA795598B (ru)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5495552A (en) *	1978-01-06	1979-07-28	Sankyo Co Ltd	Prostacyline derivative and its preparation
GB2038333B (en) *	1978-01-26	1982-10-06	Erba Farmitalia	12 -formyl- (20 12)octanor-9-deoxy-9 -methylene pgi derivatives
DE3021895A1 (de) *	1980-06-06	1981-12-24	Schering Ag Berlin Und Bergkamen, 1000 Berlin	Neues verfahren zur herstellung von carbacyclin-zwischenprodukten
DE3048906A1 (de) *	1980-12-19	1982-07-15	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3104044A1 (de) *	1981-02-02	1982-08-26	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue prostacyclin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE3121155A1 (de) *	1981-05-22	1982-12-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3204443A1 (de) *	1982-02-08	1983-08-18	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4533749A (en) *	1982-02-16	1985-08-06	The Upjohn Company	9-Substituted carbacyclin analogs
DE3306125A1 (de) *	1983-02-18	1984-08-23	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4486598A (en) *	1982-02-22	1984-12-04	The Upjohn Company	Carbacyclin analogs
DE3225287A1 (de) *	1982-07-02	1984-01-05	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue carbacyclinamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HU191110B (en) *	1982-10-01	1987-01-28	Farmitala Carlo Erba Spa,It	Process for the production of the 15-cycloaliphatic derivatives 13,14-didehydro-carbaprostacyclines
GB2129427B (en) *	1982-10-01	1986-01-08	Erba Farmitalia	15-cycloaliphatic derivatives of 13,14-didehydrocarboprostacyclins and process for their preparation
ES8705382A1 (es) *	1983-07-26	1987-05-01	Sankyo Co	Un procedimiento para la preparacion de nuevos derivados de carbaciclina.
DE3408699A1 (de) *	1984-03-08	1985-09-12	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB2156341B (en) *	1984-03-26	1987-10-21	Erba Farmitalia	Furyl and imidazolyl derivatives of carboprostacyclins and process for their preparation
GB2156343B (en) *	1984-03-26	1988-01-13	Erbo Spa Farmitalia Carlo	13,14,19,19,20,20-hexadehydro derivatives of carboprostacyclins and process for their preparation
DE3448257C2 (en) *	1984-07-25	1988-08-18	Schering Ag, 1000 Berlin Und 4709 Bergkamen, De	Cytoprotective action of prostacyclin derivatives on the kidney
DE3448256C2 (en) *	1984-07-25	1988-08-18	Schering Ag, 1000 Berlin Und 4709 Bergkamen, De	Cytoprotective action of prostacyclin derivatives on the pancreas
DE3428266A1 (de) *	1984-07-27	1986-01-30	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3678472D1 (de) *	1985-03-18	1991-05-08	Searle & Co	Allenische prostacycline.
JPS6216A (ja) *	1985-03-19	1987-01-06	Sankyo Co Ltd	カルバサイクリン類及びこれを有効成分とする抗潰瘍剤
DE3608088C2 (de) *	1986-03-07	1995-11-16	Schering Ag	Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3631169A1 (de) *	1986-09-11	1988-03-24	Schering Ag	Prostacyclinderivate enthaltende mittel fuer die topische anwendung
US5663203A (en) *	1986-09-11	1997-09-02	Schering Aktiengesellschaft	Agents containing prostacyclin derivatives for topical application
US5221763A (en) *	1987-04-30	1993-06-22	R-Tech Ueno, Ltd.	Prostaglandins of the F series
WO1989000559A1 (en)	1987-07-17	1989-01-26	Schering Aktiengesellschaft Berlin Und Bergkamen	9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs
US5891910A (en) *	1987-07-17	1999-04-06	Schering Aktiengesellschaft	9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents
DE3839155A1 (de) *	1988-11-17	1990-05-23	Schering Ag	Verfahren zur herstellung von carbacyclin-derivaten durch stereoselektive einfuehrung der 5,6-doppelbindung
DE4010355A1 (de) *	1990-03-28	1991-10-02	Schering Ag	Bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4104607A1 (de) *	1991-02-12	1992-08-13	Schering Ag	Prostacyclin- und carbacyclinderivate als mittel zur behandlung von fiebrigen erkrankungen
DE4104606C1 (ru) *	1991-02-12	1992-10-15	Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
DE4135193C1 (ru) *	1991-10-22	1993-03-11	Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
WO1994003175A1 (de) *	1992-08-07	1994-02-17	Schering Aktiengesellschaft	Verwendung von prostanderivaten zur herstellung eines arzneimittels zur behandlung der chronischen polyarthritis
US5534589A (en) *	1994-05-04	1996-07-09	Minnesota Mining And Manufacturing Company	Repulpable plastic films
JP3783873B2 (ja) *	1994-06-07	2006-06-07	中外製薬株式会社	肺における類線維素形成又は血栓形成に起因する疾患の予防及び治療薬並びに該疾患のモデル動物
DE19530884C2 (de) *	1995-08-11	1997-07-31	Schering Ag	Verwendung von Prostan-Derivaten sowie deren Kombination mit Antibiotika zur Behandlung von bakteriellen Meningitis
DE19828881A1 (de) *	1998-06-22	1999-12-23	Schering Ag	Oxidationsinhibitor bei Prostan-Derivaten
WO2000002450A1 (en) *	1998-07-08	2000-01-20	Fibrogen, Inc.	Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
JP3835763B2 (ja)	2002-08-19	2006-10-18	ファイザー・プロダクツ・インク	増殖亢進疾患のための組み合わせ治療
EP1563845A4 (en) *	2002-10-10	2008-02-20	Univ Kyoto	REMEDIES FOR ALLERGIC DISEASES
US20050043391A1 (en) *	2003-07-17	2005-02-24	Fong Benson M.	Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
WO2005009468A1 (ja)	2003-07-25	2005-02-03	Ono Pharmaceutical Co., Ltd.	軟骨関連疾患治療剤
US20090124697A1 (en)	2003-12-16	2009-05-14	United Therapeutics Corporation	Inhalation formulations of treprostinil
WO2005058303A1 (en) *	2003-12-16	2005-06-30	United Therapeutics Corporation	Use of treprostinil to treat and prevent ischemic lesions
MX2007000979A (es) *	2004-07-26	2007-07-11	Cotherix Inc	Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
EP2351569B1 (en)	2005-10-26	2012-08-22	Asahi Kasei Pharma Corporation	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2111863B1 (en)	2005-10-26	2012-03-28	Asahi Kasei Pharma Corporation	Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
WO2007134292A2 (en)	2006-05-15	2007-11-22	United Therapeutics Corporation	Treprostinil administration using a metered dose inhaler
DE102006026786A1 (de)	2006-06-07	2007-12-13	Joachim Kern	Dosierinhalator
US8183286B2 (en) *	2006-11-16	2012-05-22	Gemmus Pharma Inc.	EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
ES2382009T3 (es)	2006-12-01	2012-06-04	Bristol-Myers Squibb Company	Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
EP2065054A1 (en)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Combinations comprising a prostaglandin and uses thereof
NO2315587T3 (ru)	2008-08-13	2018-03-24
WO2011047048A1 (en)	2009-10-14	2011-04-21	Gemmus Pharma, Inc.	Combination therapy treatment for viral infections
KR101701943B1 (ko)	2009-11-13	2017-02-02	도레이 카부시키가이샤	당뇨병의 치료 또는 예방약
BR112015026513A2 (pt)	2013-04-17	2017-07-25	Pfizer	derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CA2920856A1 (en)	2013-08-09	2015-02-12	Ardelyx, Inc.	Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
US10799653B2 (en)	2017-01-09	2020-10-13	United Therapeutics Corporation	Aerosol delivery device and method for manufacturing and operating the same
EA202191892A1 (ru)	2019-01-18	2022-02-24	Астразенека Аб	Ингибиторы pcsk9 и способы их применения
JP2022533251A (ja)	2019-05-21	2022-07-21	アルデリックス，インコーポレイテッド	患者において血清リン酸塩を低下させるための組み合わせ
AU2021255621A1 (en)	2020-04-17	2022-10-20	United Therapeutics Corporation	Treprostinil for use in the treatment of intersitial lung disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4097489A (en) *	1977-06-17	1978-06-27	The Upjohn Company	9-Deoxy-9α,6-nitrilo or 6,9α-imino-PGF compounds
JPS5495552A (en) *	1978-01-06	1979-07-28	Sankyo Co Ltd	Prostacyline derivative and its preparation
GB2038333B (en) *	1978-01-26	1982-10-06	Erba Farmitalia	12 -formyl- (20 12)octanor-9-deoxy-9 -methylene pgi derivatives
US4238414A (en) *	1978-02-13	1980-12-09	The Upjohn Company	2-Decarboxy-2-aminomethyl-6a-carba-PGI2 compounds
JPS54119441A (en) *	1978-03-09	1979-09-17	Sumitomo Chem Co Ltd	Novel bicyclooctane derivative
JPS54130543A (en) *	1978-03-31	1979-10-09	Ono Pharmaceut Co Ltd	Prostagladin i2 analog, and its preparation
JPS5528945A (en) *	1978-08-22	1980-02-29	Sankyo Co Ltd	Prostacycline-family compound and its preparation

1978
- 1978-10-19 DE DE19782845770 patent/DE2845770A1/de not_active Withdrawn
1979
- 1979-10-07 GR GR60293A patent/GR72247B/el unknown
- 1979-10-16 DD DD79216259A patent/DD146594B3/de not_active IP Right Cessation
- 1979-10-17 IL IL58475A patent/IL58475A/xx unknown
- 1979-10-18 YU YU2530/79A patent/YU41668B/xx unknown
- 1979-10-18 AT AT79710099T patent/ATE1283T1/de active
- 1979-10-18 PH PH23193A patent/PH20359A/en unknown
- 1979-10-18 EP EP79710099A patent/EP0011591B1/de not_active Expired
- 1979-10-18 NO NO793353A patent/NO151318C/no unknown
- 1979-10-18 SU SU792837202A patent/SU1003754A3/ru active
- 1979-10-18 DE DE7979710099T patent/DE2963260D1/de not_active Expired
- 1979-10-18 HU HU79SCHE698A patent/HU184926B/hu unknown
- 1979-10-19 ZA ZA00795598A patent/ZA795598B/xx unknown
- 1979-10-19 FI FI793263A patent/FI69056C/fi not_active IP Right Cessation
- 1979-10-19 CA CA000338081A patent/CA1181747A/en not_active Expired
- 1979-10-19 AU AU51987/79A patent/AU534090B2/en not_active Expired
- 1979-10-19 NZ NZ191827A patent/NZ191827A/xx unknown
- 1979-10-19 DK DK441479A patent/DK160246C/da not_active IP Right Cessation
- 1979-10-19 ES ES485199A patent/ES485199A1/es not_active Expired
- 1979-10-19 JP JP13503779A patent/JPS5557559A/ja active Granted
- 1979-10-19 IE IE1993/79A patent/IE49085B1/en not_active IP Right Cessation
- 1979-10-19 CS CS797108A patent/CS219260B2/cs unknown
1981
- 1981-02-12 SU SU813242701A patent/SU1310390A1/ru active
1982
- 1982-02-26 US US06/352,411 patent/US4692464A/en not_active Expired - Lifetime
1992
- 1992-06-29 MX MX9203690A patent/MX9203690A/es unknown
1993
- 1993-06-09 LU LU88288C patent/LU88288I2/fr unknown
- 1993-06-14 NL NL930070C patent/NL930070I2/nl unknown
1995
- 1995-12-19 NO NO1995010C patent/NO1995010I1/no unknown

Also Published As

Publication number	Publication date
NO1995010I1 (no)	1995-12-19
CA1181747A (en)	1985-01-29
EP0011591A1 (de)	1980-05-28
NO151318B (no)	1984-12-10
IL58475A (en)	1989-09-10
SU1003754A3 (ru)	1983-03-07
EP0011591B1 (de)	1982-06-30
FI69056C (fi)	1985-12-10
DK160246B (da)	1991-02-18
FI69056B (fi)	1985-08-30
CS219260B2 (en)	1983-03-25
YU253079A (en)	1983-01-21
ATE1283T1 (de)	1982-07-15
NL930070I1 (nl)	1993-09-01
IE49085B1 (en)	1985-07-24
MX9203690A (es)	1992-09-01
PH20359A (en)	1986-12-04
NZ191827A (en)	1982-05-25
FI793263A (fi)	1980-04-20
NL930070I2 (nl)	1994-01-03
DE2845770A1 (de)	1980-04-30
IL58475A0 (en)	1980-01-31
ZA795598B (en)	1980-10-29
IE791993L (en)	1980-04-19
AU534090B2 (en)	1984-01-05
US4692464A (en)	1987-09-08
JPS6312051B2 (ru)	1988-03-17
DD146594A5 (de)	1981-02-18
ES485199A1 (es)	1980-05-16
NO151318C (no)	1985-03-20
LU88288I2 (fr)	1994-05-04
AU5198779A (en)	1980-04-24
SU1310390A1 (ru)	1987-05-15
DK441479A (da)	1980-04-20
HU184926B (en)	1984-11-28
GR72247B (ru)	1983-10-05
YU41668B (en)	1987-12-31
NO793353L (no)	1980-04-22
DK160246C (da)	1991-07-22
JPS5557559A (en)	1980-04-28
DE2963260D1 (en)	1982-08-19

Legal Events

Date	Code	Title	Description
1998-06-04	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD146594B3 (de)	1989-09-06	Verfahren zur herstellung von prostanderivaten
EP0055208B1 (de)	1985-03-13	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4359467A (en)	1982-11-16	Prostanoic acid derivatives and their preparation
US4073934A (en)	1978-02-14	Novel acetylenic prostaglandin analogs
DE3306123A1 (de)	1984-09-06	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0099538B1 (de)	1991-09-11	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0051558B1 (de)	1984-03-28	Prostacyclinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0069692B1 (de)	1988-03-02	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0105288B1 (de)	1985-12-11	Carbacycline, herstellung und verwendung
EP0086404B1 (de)	1986-12-30	Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0094951B1 (de)	1985-10-30	Neue prostacycline und verfahren zu ihrer herstellung
EP0051557B1 (de)	1984-03-14	5-Cyan-prostacyclinderivate, Verfahren zu ihrer Herstellung und ihrer Verwendung als Arzneimittel
EP0113311B1 (de)	1992-01-02	5-Fluorcarbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0058632B1 (de)	1984-04-11	(13E)-(8R,11R,12R)-11,15-Dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadiensäuren sowie deren Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DD210028B3 (de)	1990-06-13	Verfahren zur herstellung von carbacyclinderivaten
DE3308561A1 (de)	1984-09-13	19,20-methylenprostacyclinderivate und verfahren zu ihrer herstellung
EP0163672A1 (de)	1985-12-11	20-alkyl-7-oxoprostacyclinderivate und verfahren zu ihrer herstellung.
DD234414A5 (de)	1986-04-02	Verfahren zur herstellung neuer carbacycline
WO1987005900A1 (en)	1987-10-08	7-oxoprostacycline derivatives and process for their manufacture
DE3306125A1 (de)	1984-08-23	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD202010A5 (de)	1983-08-24	Verfahren zur herstellung neuer carbacycline